Social media

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Antibody-drug conjugates (ADCs) are transforming cancer treatment — but measuring free payload concentrations is critical to ensure their safety and efficacy. Even the smallest impurity can skew results. Discover how adv...

Are your trials measuring what matters to patients…or just what’s easiest to capture? It’s no longer enough to only drive outcomes. Rather, we must drive outcomes that matter to patients. In this whitepaper, we outlin...

Tired of stitching together fragmented market data? Metys®, from Symphony Health, an ICON plc company, is the only fully integrated platform that consolidates over 150 metrics and dimensions – giving you a complete, rea...

Tired of stitching together fragmented market data? Metys®, from Symphony Health, an ICON plc company, is the only fully integrated platform that consolidates over 150 metrics and dimensions – giving you a complete, rea...

For the second article in our new series, we delve deeper into ISO 14971 (Application of risk management to medical devices). We discuss a history of risk-based thinking and common misunderstandings around risk analysis ...

For the second article in our new series, we delve deeper into ISO 14971 (Application of risk management to medical devices). We discuss a history of risk-based thinking and common misunderstandings around risk analysis ...

What happens after your JCA submission? Discover how different EU countries integrate JCA findings into local pricing and reimbursement decisions - and how to prepare. Explore the full guide: https://ow.ly/YURE50XgHt1 #...

What happens after your JCA submission? Discover how different EU countries integrate JCA findings into local pricing and reimbursement decisions - and how to prepare. Explore the full guide: https://ow.ly/YURE50XgHt1 #...

When asked what matters most, patients living with obesity ranked self-esteem, energy, social participation, and body image above all else. How can sponsors design trials that truly reflect those priorities? Learn more i...

Join ICON at booth #8 during the #OCTDACH conference, taking place 12–13 November at the Kameha Grand in Zurich, Switzerland. As a trusted partner to biotech and pharmaceutical companies across the DACH region, ICON del...

Join ICON at booth \#8 during the #OCTDACH conference, taking place 12–13 November at the Kameha Grand in Zurich, Switzerland. As a trusted partner to biotech and pharmaceutical companies across the DACH region, ICON de...